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A B S T R A C T
Background
Human albumin solutions are used in a range of medical and surgical problems. Licensed indications are the emergency treatment of
shock and other conditions where restoration of blood volume is urgent, burns, and hypoproteinaemia. Human albumin solutions are
more expensive than other colloids and crystalloids.
Objectives
To quantify the effect on mortality of human albumin and plasma protein fraction (PPF) administration in themanagement of critically
ill patients.
Search strategy
We searched the Cochrane Injuries Group trials register, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and
BIDS Index to Scientific and Technical Proceedings. Reference lists of trials and review articles were checked, and authors of identified
trials were contacted. The search was last updated in November 2002.
Selection criteria
Randomised controlled trials comparing albumin/PPF with no albumin/PPF, or with a crystalloid solution, in critically ill patients
with hypovolaemia, burns or hypoalbuminaemia.
Data collection and analysis
We collected data on the participants, albumin solution used, mortality at the end of follow up, and quality of allocation concealment.
Analysis was stratified according to patient type.
Main results
We found 31 trials meeting the inclusion criteria and reporting death as an outcome. There were 177 deaths among 1519 trial
participants.
For each patient category the risk of death in the albumin treated group was higher than in the comparison group. For hypovolaemia
the relative risk of death following albumin administration was 1.46 (95% confidence interval 0.97 to 2.22), for burns the relative risk
was 2.40 (1.11 to 5.19), and for hypoalbuminaemia the relative risk was 1.38 (0.94 to 2.03). The pooled relative risk of death with
albumin administration was 1.52 (1.17 to 1.99). Overall, the risk of death in patients receiving albumin was 14% compared to 9% in
the control groups, an increase in the risk of death of 5% (2% to 8%). These data suggest that for every 20 critically ill patients treated
with albumin there is one additional death.
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Reviewers’ conclusions
There is no evidence that albumin administration reduces the risk of death in critically ill patients with hypovolaemia, burns or
hypoalbuminaemia, and a strong suggestion that it may increase the risk of death. These data suggest that the use of human albumin
in critically ill patients should be urgently reviewed and that it should not be used outside the context of a rigorously conducted
randomised controlled trial.
P L A I N L A N G U A G E S U M M A R Y
Synopsis
No evidence that giving human albumin to replace lost blood in critically ill or injured people improves survival, and some evidence it
may do harm
Trauma, burns or surgery can cause people to lose large amounts of blood. Fluid replacement, giving fluids intravenously (into a vein),
is used to help restore blood volume and reduce the risk of dying. Blood products (including human albumin), non-blood products
or combinations can be used. The review of trials found no evidence that albumin reduces the risk of dying. Further, there is evidence
that albumin may increase the risk of death in people who are critically ill.
B A C K G R O U N D
In patients with acute and chronic illness, serum albumin concen-
tration is inversely related to mortality risk. A systematic review of
cohort studies meeting specified criteria estimated that, for each
2.5 g/L decrement in serum albumin concentration, the risk of
death increases by between 24% and 56% (Goldwasser 1997).
The association persists after adjusting for other known risk fac-
tors and pre-existing illness, suggesting a direct protective effect
of the albumin molecule (Goldwasser 1997). Largely as a result
of these observations, human albumin solutions are now used in
the management of a diverse range of medical and surgical prob-
lems. Published indications for human albumin solution include
the emergency treatment of shock and other conditions where
restoration of blood volume is urgent, the acute management of
burns, and clinical situations associated with hypoproteinaemia
(ABPI 1998).
In comparison with other colloidal solutions and with crystalloid
solutions, human albumin solutions are expensive (McClelland
1990). Volume for volume human albumin solution is twice as ex-
pensive as hydroxyethyl starch, and over thirty times more expen-
sive than crystalloid solutions such as sodium chloride or Ringer’s
lactate. Because of the high cost and limited availability of hu-
man albumin, it is particularly important that its use should be
restricted to the indications for which it has shown to be effec-
tive. To assess the effectiveness and safety of human albumin solu-
tions in themanagement of critically ill patients, particularly those
with hypovolaemia from injury or surgery, burns and hypopro-
teinaemia, a systematic review of randomised controlled trials was
conducted.
O B J E C T I V E S
To quantify the effect on mortality of human albumin adminis-
tration in the management of critically ill patients.
R E S U L T S
In each of the patient categories the risk of death in the albumin
treated group was higher than in the comparison group. For hypo-
volaemia the relative risk of death following albumin administra-
tion was 1.46 (95% confidence interval 0.97, 2.22), for burns the
relative risk was 2.40 (1.11, 5.19), and for hypoalbuminaemia the
relative risk was 1.38 (0.94, 2.03). There was no substantial het-
erogeneity between the trials in the various categories (chi-square
= 17.74, df = 24, p =/>0.2). The pooled relative risk of death with
albumin administration was 1.52 (1.17, 1.99). Overall, the risk of
death in patients receiving albumin was 14% and the risk of death
in patients not receiving albumin was 9%.When the analyses were
repeated using a random effects model, the pooled relative risk
with albumin administration was 1.35 (1.04, 1.76).
The analyseswere repeated, including only the 13 trialswith deaths
in at least one arm in which allocation concealment involved a
method thatwould be expected to reduce the risk of foreknowledge
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of treatment allocation (pharmacy controlled randomisation or
serially numbered sealed opaque envelopes). For hypovolaemia the
relative risk of death with albumin administration was 1.39 (0.80,
2.40), for burns the relative risk was 2.47 (0.69, 8.79), and for
hypoalbuminaemia the relative risk was 1.71 (0.92, 3.18). There
was no substantial heterogeneity between the trials in the various
categories (chi-square = 2.40, df = 12, p =/>0.2) and the pooled
relative risk of death with albumin administration was 1.61 (1.09,
2.38).
D I S C U S S I O N
There is no evidence that albumin reduces mortality and a strong
suggestion that it may increase the risk of death in patients with
hypovolaemia, burns and hypoproteinaemia. Overall, the risk of
death in patients treated with albumin is about 5% (95% confi-
dence interval 2%, 8%) higher than in patients not given albumin.
Mortality was selected as the outcome measure in this systematic
review for several reasons. In the context of critical illness, death
or survival is a clinically relevant outcome that is of immediate
importance to patients, and data on death are reported in nearly
all studies. Furthermore, one might expect that mortality data
would be less prone to measurement error or biased reporting
than would data on pathophysiological outcomes. The use of a
pathophysiological end point as a surrogate for an adverse outcome
assumes a direct relationship between the two, an assumption that
may sometimes be inappropriate. Finally, when trials collect data
on a number of physiological end points, there is the potential for
bias due to the selective publication of end points showing striking
treatment effects. Because we obtained mortality data for all but
four of the included trials, the likelihood of bias due to selective
publication of trial outcomes is minimal.
Although publication bias is a potent threat to the validity of sys-
tematic reviews, it is unlikely to have had an important impact in
this study. There was no evidence of funnel plot asymmetry on
visual inspection. In some of the trials included in this review, allo-
cation concealment was inadequate or was unclear. As a result, it is
possible that more severely ill patients were preferentially allocated
to the albumin treated group which may account for the increased
mortality risk in this group. Nevertheless, when the analyses were
repeated including only those trials in which allocation conceal-
ment involved a method that would be expected to reduce the risk
of foreknowledge of treatment allocation, the point estimates were
little different.
To what extent are the results of this review of 31 relatively small
randomised trials of albumin administration generalisable to clin-
ical practice? We believe that this is a matter for judgement by
the responsible clinician faced with an individual patient (Oxman
1994). However, an advantage of an overview such as ours is that
since it includes many studies, the results are based on a wide range
of patients. Because the results are consistent across the studies,
they might reasonably be taken to apply to this wide variety of
patients (Oxman 1994). Moreover, the randomised evidence that
we have brought together is, as far as we can ensure, the totality of
the available randomised evidence compared to no colloid for the
use of albumin in hypovolaemia, burns and hypoalbuminaemia,
the indications for which albumin is currently licensed.
Is there a plausible mechanism by which human albumin might
increase mortality? Albumin is used in hypovolaemia and hypoal-
buminaemia because it is believed to be effective in replacing vol-
ume and supporting colloid oncotic pressure (Soni 1995). How-
ever, albumin is also believed to have anticoagulant properties, in-
hibiting platelet aggregation and enhancing the inhibition of fac-
tor Xa by antithrombin III (Soni 1995). Such anticoagulant activ-
ity might be detrimental in critically ill patients, particularly those
with haemorrhagic hypovolaemia. Furthermore, albumin has been
shown to distribute across the capillary membrane, a process that
is accelerated in critically ill patients (Fleck 1985). It has been
suggested that increased leakage of albumin into the extravascu-
lar spaces might reduce the oncotic pressure difference across the
capillary wall, making oedema more likely (Fleck 1985).
Because this meta-analysis was based on 31 relatively small trials
in which there were only a small number of deaths, the results
must be interpreted with caution. Nevertheless, we believe that a
reasonable conclusion from these results is that the use of human
albumin in the management of critically ill patients should be
reviewed. A strong argument could be made that human albumin
should not be used outside the context of a properly concealed and
otherwise rigorously conducted randomised controlled trial with
mortality as the end point. Until such data become available, there
is also a case for a review of the licensed indications for albumin
use.
This systematic review was updated in November 2001. One ad-
ditional trial was identified and included (Bland 1973). This trial
compared albumin and dextrose infusions in new-born infants
with low cord serum protein levels who were considered to be at
risk of respiratory distress. This trial meets the eligibility criteria
for the review (hypo-proteinameia) but had been overlooked in
the original search. However, the inclusion of this trial does not
change the conclusions of the review.
Since the review was first published a number of randomised con-
trolled trials have been initiated and details of these trials are pre-
sented in the table of on-going studies. The largest of the on-going
trials is ’SAFE,’ (Saline versus Albumin Fluid Evaluation), a ran-
domised controlled trial of albumin administration in critically
ill patients. Funded primarily by the Australian National Health
andMedical ResearchCouncil, theNewZealandResearch council
and directly by Australian State and Federal Government agencies,
SAFE aims to recruit some 7000 critically ill patients and should
provide the evidence needed to resolve the current uncertainty
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about albumin.
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